Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Cash from Investing Activities: 2009-2024

Historic Cash from Investing Activities for Madrigal Pharmaceuticals (MDGL) over the last 16 years, with Dec 2024 value amounting to -$274.4 million.

  • Madrigal Pharmaceuticals' Cash from Investing Activities fell 2.28% to -$207.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.2 million, marking a year-over-year increase of 92.66%. This contributed to the annual value of -$274.4 million for FY2024, which is 45.40% up from last year.
  • As of FY2024, Madrigal Pharmaceuticals' Cash from Investing Activities stood at -$274.4 million, which was up 45.40% from -$502.5 million recorded in FY2023.
  • In the past 5 years, Madrigal Pharmaceuticals' Cash from Investing Activities registered a high of $206.7 million during FY2022, and its lowest value of -$502.5 million during FY2023.
  • Over the past 3 years, Madrigal Pharmaceuticals' median Cash from Investing Activities value was -$274.4 million (recorded in 2024), while the average stood at -$190.1 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first skyrocketed by 4,188.74% in 2022, then plummeted by 343.13% in 2023.
  • Over the past 5 years, Madrigal Pharmaceuticals' Cash from Investing Activities (Yearly) stood at $159.8 million in 2020, then slumped by 103.16% to -$5.1 million in 2021, then soared by 4,188.74% to $206.7 million in 2022, then slumped by 343.13% to -$502.5 million in 2023, then soared by 45.40% to -$274.4 million in 2024.